A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors

Cancer Gene Therapy

Volumn 19, Issue 10, 2012, Pages 667-674

  Wieking, B G ^a   Vermeer, D W ^a   Spanos, W C ^a,b   Lee, K M ^a   Vermeer, P ^a   Lee, W T ^c   Xu, Y ^d   Gabitzsch, E S ^d   Balcaitis, S ^d   Balint, J P ^d   Jones, F R ^d   Lee, J H ^a,b  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

^b Sanford Health ^*  (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d Etubics Corporation   (United States)

Author keywords

adenovirus; E6; E7; head and neck cancer; HPV; immunotherapy

Indexed keywords

ADENOVIRUS VECTOR; CISPLATIN; GLYCOPROTEIN E1; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 13; PROTEIN E2B; PROTEIN E6; PROTEIN E7; PROTEIN P53; RETINOBLASTOMA PROTEIN; TELOMERASE; UNCLASSIFIED DRUG; VIRUS PROTEIN; WART VIRUS VACCINE;

ADENOCARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENICITY; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; ENZYME ACTIVATION; EPITHELIUM BASAL CELL; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; MALE; MOUSE; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TUMOR; VIRUS MUTATION;

ADENOCARCINOMA; ADENOVIRIDAE; ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MUTAGENESIS, SITE-DIRECTED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; REPRESSOR PROTEINS;

ADENOVIRIDAE; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRIDAE;

EID: 84866380714     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.55     Document Type: Article

References (40)

1. Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends in the US population ages 20-44 years. Cancer 2005; 103: 1843-1849.
2. Hammarstedt L, Dahlstrand H, Lindquist D, Onelov L, Ryott M, Luo J et al. The incidence of tonsillar cancer in Sweden is increasing. Acta Otolaryngol 2007; 127: 988-992.
3. Smith EM, Ritchie JM, Summersgill KF, Klussmann JP, Lee JH, Wang D et al. Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer 2004; 108: 766-772.
4. Ritchie JM, Smith EM, Summersgill KF, Hoffman HT, Wang D, Klussmann JP et al. Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer 2003; 104: 336-344.
5. Smeets SJ, van der Plas M, Schaaij-Visser TB, van Veen EA, van Meerloo J, Braakhuis BJ et al. Immortalization of oral keratinocytes by functional inactivation of the p53 and pRb pathways. Int J Cancer 128: 1596-1605.
6. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-1136.
7. Veldman T, Liu X, Yuan H, Schlegel R. Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc Nat Acad Sci USA 2003; 100: 8211-8216.
8. Spanos WC, Hoover A, Harris GF, Wu S, Strand GL, Anderson ME et al. The PDZ binding motif of human papillomavirus type 16 E6 induces PTPN13 loss, which allows anchorage-independent growth and synergizes with ras for invasive growth. J Virol 2008; 82: 2493-2500.
9. Brehm A, Nielsen SJ, Miska EA, McCance DJ, Reid JL, Bannister AJ et al. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J 1999; 18: 2449-2458.
10. Munger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol 2004; 78: 11451-11460.
11. D'Abramo CM, Archambault J. Small molecule inhibitors of human papillomavirus protein-protein interactions. Open Virol J 2011; 5: 80-95.
12. Berry JM, Palefsky JM. A review of human papillomavirus vaccines: from basic science to clinical trials. Front Biosci 2003; 8: s333-s345.
13. Duray A, Descamps G, Bettonville M, Sirtaine N, Ernoux-Neufcoeur P, Guenin S et al. High prevalence of high-risk human papillomavirus in palatine tonsils from healthy children and adults. Otolaryngol Head Neck Surg 2011; 145: 230-235.
14. FUTUREIIStudyGroup. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-1927.
15. Lee DW, Anderson ME, Wu S, Lee JH. Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomaviruspositive cancer. Arch Otolaryngol 2008; 134: 1316-1323.
16. Spanos WC, Nowicki P, Lee DW, Hoover A, Hostager B, Gupta A et al. Immune response during therapy with cisplatin or radiation for human papillomavirusrelated head and neck cancer. Arch Otolaryngol 2009; 135: 1137-1146.
17. Amalfitano A, Hauser MA, Hu H, Serra D, Begy CR, Chamberlain JS. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol 1998; 72: 926-933.
18. Nguyen DX, Westbrook TF, McCance DJ. Human papillomavirus type 16 E7 maintains elevated levels of the cdc25A tyrosine phosphatase during deregulation of cell cycle arrest. J Virol 2002; 76: 619-632.
19. Gabitzsch ES, Xu Y, Yoshida LH, Balint J, Amalfitano A, Jones FR. Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity. Vaccine 2009; 27: 6394-6398.
20. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996; 70: 7498-7509.
21. Williams R, Lee DW, Elzey BD, Anderson ME, Hostager BS, Lee JH. Preclinical models of HPV + and HPV-HNSCC in mice: an immune clearance of HPV + HNSCC. Head Neck 2009; 31: 911-918.
22. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015.
23. Kim NW, Wu F. Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). Nucleic Acids Res 1997; 25: 2595-2597.
24. Gabitzsch ES, Xu Y, Yoshida LH, Balint J, Gayle RB, Amalfitano A et al. A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses. Immunol Lett 2009; 122: 44-51.
25. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75: 495-505.
26. Lee SS, Weiss RS, Javier RT. Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosophila discs large tumor suppressor protein. Proc Nat Acad Sci USA 1997; 94: 6670-6675.
27. van Ham M, Hendriks W. PDZ domains-glue and guide. Mol Biol Rep 2003; 30: 69-82.
28. Peters DM, Dowd N, Brandt C, Compton T. Human papilloma virus E6/E7 genes can expand the lifespan of human corneal fibroblasts. In vitro Cell Dev Biol 1996; 32: 279-284.
29. Hoover AC, Spanos WC, Harris GF, Anderson ME, Klingelhutz AJ, Lee JH. The role of human papillomavirus 16 E6 in anchorage-independent and invasive growth of mouse tonsil epithelium. Arch Otolaryngol 2007; 133: 495-502.
30. Gabitzsch ES, Xu Y, Balcaitis S, Balint Jr JP , Jones FR. An Ad5[E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice. Cancer Gene Ther 2011; 18: 326-335.
31. Gabitzsch ES, Xu Y, Balint Jr. JP , Hartman ZC, Lyerly HK, Jones FR. Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA. Cancer Immunol Immunother 2010; 59: 1131-1135.
32. Shafer-Weaver K, Sayers T, Strobl S, Derby E, Ulderich T et al. The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. J Transl Med 2003; 1: 1479-5876.
33. Osada T, Yang XY, Hartman ZC, Glass O, Hodges BL, Niedzwiecki D et al. Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity. Cancer Gene Ther 2009; 16: 673-682.
34. Gabitzsch ES, Xu Y, Balint Jr JP , Balcaitis S, Sanders-Beer B, Jones FR. Induction and comparison of SIV immunity in Ad5 naive and Ad5 immune non-human primates using an AD5 [E1-, E2b-] based vaccine. Vaccine 2011; 29: 8101-8107.
35. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996; 347: 1523-1527.
36. Baldwin PJ, van der Burg SH, Boswell CM, Offringa R, Hickling JK, Dobson J et al. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res 2003; 9: 5205-5213.
37. Davidson EJ, Boswell CM, Sehr P, Pawlita M, Tomlinson AE, McVey RJ et al. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res 2003; 63: 6032-6041.
38. Lin CT, Tsai YC, He L, Calizo R, Chou HH, Chang TC et al. A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity. J Biomed Sci 2006; 13: 481-488.
39. Peng S, Ji H, Trimble C, He L, Tsai YC, Yeatermeyer J et al. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol 2004; 78: 8468-8476.
40. Karanam B, Gambhira R, Peng S, Jagu S, Kim DJ, Ketner GW et al. Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine 2009; 27: 1040-1049.